Wall Street Zen Downgrades Agenus (NASDAQ:AGEN) to Hold
by Doug Wharley · The Cerbat GemAgenus (NASDAQ:AGEN – Get Free Report) was downgraded by Wall Street Zen from a “strong-buy” rating to a “hold” rating in a report issued on Monday.
Several other brokerages also recently issued reports on AGEN. Zacks Research downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. B. Riley Financial reissued a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Finally, Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $19.50.
View Our Latest Analysis on Agenus
Agenus Stock Performance
Shares of Agenus stock opened at $7.53 on Monday. The firm has a market cap of $339.00 million, a PE ratio of 2.92 and a beta of 1.40. The business’s 50 day simple moving average is $5.01 and its 200 day simple moving average is $4.01. Agenus has a 52-week low of $2.71 and a 52-week high of $8.85.
Agenus (NASDAQ:AGEN – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%.The business had revenue of $34.52 million for the quarter, compared to the consensus estimate of $34.00 million. As a group, equities research analysts predict that Agenus will post -0.28 EPS for the current year.
Institutional Trading of Agenus
Several large investors have recently bought and sold shares of AGEN. EP Wealth Advisors LLC acquired a new stake in Agenus in the fourth quarter valued at approximately $31,000. R Squared Ltd acquired a new position in shares of Agenus during the fourth quarter worth $41,000. Redwood Family Wealth LLC bought a new position in shares of Agenus in the 4th quarter valued at $44,000. Quadrature Capital Ltd acquired a new stake in shares of Agenus during the 4th quarter valued at $54,000. Finally, Squarepoint Ops LLC bought a new stake in Agenus during the 3rd quarter worth $54,000. 61.46% of the stock is owned by institutional investors and hedge funds.
Agenus Company Profile
Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.